Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disposition and Absolute Bioavailability of Naperiglipron in Healthy Participants
NCT06194500Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2024
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of naperiglipron in type 2 diabetes mellitus (T2DM) and obesity (2 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Urinary Excretion of Total Radioactivity, Fecal Excretion of Total Radioactivity and 2 more. Started Jan 2024; status: completed.
02
Drugs
naperiglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06194500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194500.